Literature DB >> 8587227

High-intensity focused ultrasound (HIFU) in the treatment of benign prostatic hyperplasia (BPH).

T Ebert1, M Graefen, S Miller, D Saddeler, B Schmitz-Dräger, R Ackermann.   

Abstract

Transurethral resection of the prostate (TURP) and open adenectomy are regarded the golden standard in the management of patients with symptomatic benign prostatic hyperplasia (BPH). Various alternative treatment forms (microwaves, laser, radiofrequency, focused ultrasound) have been introduced recently. They all aim at reduction of morbidity related to TURP keeping a comparable efficacy at the same time. Since December 1992, 50 patients with BPH have been treated by high intensity focused ultrasound (HIFU-P) at our department. Six weeks following HIFU-P mean Qmax improved from 5.7 ml/s to 11.6 ml/s. Post voiding residual volume (RV) dropped from 215 ml to 100 ml, the International Prostate Symptom Score (IPSS) from 19.8 to 9.9. Both, IPSS and RV further improved during the following weeks. Follow-up data one year after treatment demonstrate that results remained stable in the majority of patients. Urinary tract infections were observed in 3 patients, macrohematospermia in all and macrohematuria (caused by the suprapubic catheter) requiring blood transfusion in 1 patient.

Entities:  

Mesh:

Year:  1995        PMID: 8587227     DOI: 10.2302/kjm.44.146

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  2 in total

1.  Application of high-intensity focused ultrasound for fetal therapy: experimental study using an animal model of lower urinary tract obstruction.

Authors:  Hiroko Aoki; Kiyotake Ichizuka; Mitsuyoshi Ichihara; Ryu Matsuoka; Junichi Hasegawa; Takashi Okai; Shinichirou Umemura
Journal:  J Med Ultrason (2001)       Date:  2012-09-08       Impact factor: 1.314

2.  Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate.

Authors:  G J Van Leenders; H P Beerlage; E T Ruijter; J J de la Rosette; C A van de Kaa
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.